Ultragenyx Pharmaceutical (RARE) 10-K2017 FY Annual report

Filed: 21 Feb 18, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: AAV, absent, accident, advocacy, affiliate, AGL, alanine, alfa, alkaline, ALT, aminotransferase, ammonia, AMT, analogized, assay, asymptomatic, autism, automation, Bayer, BEAT, BFI, biomarker, Biopharma, bioreactor, biosafety, bodily, BPI, brachial, built, Bulletin, Buphenyl, burden, burosumab, Cambridge, capsid, car, carbohydrate, caution, child, citrullinemia, clearance, CMO, CNS, collagen, commensurate, companion, compatible, compression, conceived, congressional, constrained, constraint, construed, coronary, correctly, crossover, CTD, CTx, cutoff, Deborah, debranching, deposit, diagnostic, dictated, died, dietary, Dimension, division, DNA, DTX, Dunsire, durable, ectopic, element, embryonic, endurance, entirety, enzymatic, epidural, exceeding, feeding, femoral, flexibility, footprint, forma, fracture, France, fundamental, FVIII, GDPR, GI, Glybera, glycerol, glycogen, gold, goodwill, greatest, GSDIa, GSDIII, headquartered, HeLa, hemofiltration, hemophilia, hepatomegaly, histomorphometric, hyperammonemic, hyperlipidemia, hyperphosphatemia, hypotonia, hypotrophy, Ia, IBC, immaterial, immortal, immunologic, incomplete, industrywide, ineligible, insertion, insertional, interrelated, IRC, isolated, Lastly, Laupheim, learning, lengthier, leukemia, lifecycle, limb, lipid, live, lived, living, logistical, logo, LUXTURNA, MA, majeure, malignant, mammalian, mark, mediated, Mepsevii, MepseviiTM, merger, mesenchymal, mission, MPSVII, multicenter, myocardial, Myriad, nascent, nasogastric, neparvovec, neutralizing, nitrogen, nonsteroidal, nontransferable, notification, nucleic, OBA, obsolescence, oldest, operationally, opioid, ornithine, OTC, overnight, pair, paired, paroxysmal, PCAOB, PDUFA, Penn, Pennsylvania, percentile, persistent, phenylbutyrate, phenylketonuria, phosphatase, PKU, PMA, POC, provisional, PRV, RAC, radial, Ravicti, REGENX, REGENXBIO, repaid, replication, RGIC, rich, routinely, SAB, sanctioning, scavenging, School, sequence, Similarly, simultaneously, Slight, sodium, solution, Spark, spread, standalone, straightforward, stricter, stylized, Subfield, surface, systematic, tangible, tapering, theoretical, thoracic, threshold, tooth, toothache, topline, transaminase, transcarbamylase, transfect, transformation, transplant, treatable, tube, UltraCare, unavailable, unconstrained, underway, unforeseen, uniQure, unrepatriated, unsafe, urea, vascular, vector, vestronidase, viability, VII, voretigene, voucher, washout, Wilson, Woburn, word, workforce

Removed: AAIPharma, Academy, acuity, adjusting, Alexion, American, ascribed, atrophy, autosomal, BioMarin, Biotechnologie, biweekly, born, carbon, cardiomyopathy, caregiver, climb, coding, confirmation, consecutive, converted, count, Cremer, curable, deficit, dependence, die, distal, dynamometry, erythema, escalating, exercising, extrapolated, fine, flexion, gastrointestinal, hepatosplenomegaly, hereditary, HIBM, HRG, Impression, improve, incorporating, initiating, intervention, kg, mannac, mannosamine, matrix, metabolite, mineral, misrepresentation, muscular, Neurology, neuromuscular, neutrophil, Nobelpharma, odd, onset, partnering, pattern, predefined, promulgated, pronounced, publication, reclassified, rendered, responder, rest, revaluation, revised, rimmed, Roche, Sanofi, Sanyo, Shire, shoulder, sialic, Society, solid, stair, Steering, suggest, sum, tablet, terminating, tolerated, uptake, visual, wasting, WMS, Yen, younger, Zealand

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated RARE transcripts

RARE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)

In connection with the accompanying Annual Report of Ultragenyx Pharmaceutical Inc. (the “Company”) on Form 10-K for the year ended December 31, 2017 (the “Report”), I, Emil D. Kakkis, M.D., Ph.D., as President and Chief Executive Officer of the Company, and Shalini Sharp, as Chief Financial Officer and Executive Vice President of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 21, 2018		/s/ Emil D. Kakkis
		Emil D. Kakkis, M.D., Ph.D.
		President and Chief Executive Officer (Principal Executive Officer)

Dated: February 21, 2018		/s/ Shalini Sharp
		Shalini Sharp
		Chief Financial Officer and Executive Vice President (Principal Financial Officer)